HCA Healthcare Delivers Q2 2026 Results, Declares Dividend, and Updates Guidance

summarizeSummary

HCA Healthcare reported Q2 2026 revenue up 8.7% to $20.23B and EPS of $7.62, but cut full-year guidance on rising uncompensated care. A $0.78 dividend was declared and $2.06B in shares were repurchased.

check_boxKey Events · Earnings and Guidance · HCA

• Q2 Revenue and EPS Beat

  Driven by higher admissions and a $400 million boost from Florida Medicaid supplemental payments, revenue climbed 8.7% to $20.23 billion while diluted EPS rose 11.6% to $7.62.

• Payer Mix Headwind

  An estimated $400 million unfavorable impact from increased uninsured volume—largely patients losing exchange coverage—partially offset the Medicaid benefit.

• Full-Year Guidance Cut

  EPS guidance for 2026 was lowered to $28.70–$30.50 from $29.10–$31.50, with the health insurance exchange impact now projected at $1.0–$1.2 billion, up from $600–$900 million.

• Dividend and Buybacks

  The board declared a quarterly dividend of $0.78 per share, payable September 30, and the company repurchased 4.752 million shares for $2.064 billion in Q2, leaving $7.21 billion under its authorization.

auto_awesomeAnalysis · HCA · Industrial Applications And Services

Second-quarter revenue reached $20.23 billion and EPS came in at $7.62, topping expectations even as a $400 million headwind from rising uninsured volumes—tied to the expiration of ACA subsidies—weighed on results. That pressure was fully offset by a $400 million benefit from a Florida Medicaid program, leaving net income essentially flat year over year. Looking ahead, full-year EPS guidance was trimmed to $28.70–$30.50, reflecting a deteriorating payer mix, while a newly declared $0.78 quarterly dividend and aggressive buybacks underscore management's confidence in cash generation. The balance sheet carries $49.7 billion in debt against $1.0 billion in cash, but year-to-date operating cash flow remains robust at $4.3 billion.